fb tracking

Petition to the FDA to Strengthen Safety Warning for Botox and Related Drugs and Remove Misleading Claims From Botox/Botox Cosmetic Labeling

View press release
View background document
View Petition

Public Citizen petitioned the Food and Drug Administration (FDA) to promptly emphasize the risk of iatrogenic botulism in the labeling of approved botulinum-toxin drugs (such as Botox and related drugs) and remove misleading promotional claims from Botox and Botox Cosmetic labeling.

June 3, 2024, FDA interim response letter.

December 13, 2023, FDA acknowledgment letter.

View our work related to botulinum-toxin products.